BeOne Medicines Ltd. - Sponsored ADR $ONC Shares Bought by Bank of America Corp DE

Key Points

• Bank of America increased its BeOne Medicines stake by 7% in the first quarter, owning 405,273 shares valued at approximately $120.4 million, or 0.37% of the company. Institutional investors and hedge funds collectively own 48.55% of ONC.
• BeOne reported stronger-than-expected quarterly results, with EPS of $2.05 versus the $1.40 consensus estimate and revenue of $1.71 billion versus $1.66 billion expected.
• Analyst sentiment remains positive: the stock has a “Moderate Buy” consensus rating and an average price target of $400, while several firms recently raised their targets. ONC opened at $329.80, with a market capitalization of roughly $36.2 billion.

Bank of America Corp DE grew its holdings in BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 7.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 405,273 shares of the company's stock after buying an additional 26,441 shares during the quarter. Bank of America Corp DE owned 0.37% of BeOne Medicines worth $120,354,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Capital International Investors increased its holdings in BeOne Medicines by 1.3% in the 4th quarter. Capital International Investors now owns 5,113,866 shares of the company's stock worth $1,553,909,000 after acquiring an additional 67,808 shares in the last quarter. Siren L.L.C. lifted its stake in BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company's stock valued at $151,905,000 after buying an additional 7,010 shares in the last quarter. Morgan Stanley boosted its holdings in BeOne Medicines by 23.9% in the 4th quarter. Morgan Stanley now owns 437,661 shares of the company's stock worth $132,966,000 after buying an additional 84,367 shares during the last quarter. Candriam S.C.A. boosted its holdings in BeOne Medicines by 31.7% in the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company's stock worth $77,132,000 after buying an additional 62,470 shares during the last quarter. Finally, Man Group plc increased its stake in BeOne Medicines by 18.9% during the 4th quarter. Man Group plc now owns 248,514 shares of the company's stock worth $75,501,000 after buying an additional 39,498 shares in the last quarter. 48.55% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ONC. Wells Fargo & Company initiated coverage on BeOne Medicines in a report on Monday, May 4th. They set an "overweight" rating and a $400.00 target price for the company. Barclays lifted their price target on BeOne Medicines from $403.00 to $407.00 and gave the stock an "overweight" rating in a research note on Thursday. Leerink Partners boosted their price target on BeOne Medicines from $364.00 to $367.00 and gave the stock an "outperform" rating in a research report on Friday, May 15th. Citizens Jmp increased their price objective on BeOne Medicines from $396.00 to $405.00 and gave the company a "market outperform" rating in a research note on Thursday. Finally, Citigroup restated an "outperform" rating on shares of BeOne Medicines in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, BeOne Medicines presently has an average rating of "Moderate Buy" and an average target price of $400.00.

BeOne Medicines Stock Up 0.7%

Shares of NASDAQ:ONC opened at $329.80 on Friday. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average of $295.31 and a two-hundred day moving average of $308.62. The stock has a market cap of $36.19 billion, a P/E ratio of 58.06 and a beta of 0.49. BeOne Medicines Ltd. - Sponsored ADR has a 52-week low of $253.95 and a 52-week high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.85% and a net margin of 10.70%.The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.66 billion. On average, research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post 5.93 earnings per share for the current year.

More BeOne Medicines News

Here are the key news stories impacting BeOne Medicines this week:

• Positive Sentiment: Strong Q2 performance: BeOne reported earnings of $2.05 per share, exceeding the $1.40 consensus estimate by $0.65. Revenue reached $1.71 billion, above the $1.66 billion forecast, with quarterly revenue reportedly up 30% year over year. The substantial earnings beat supports the view that the company’s oncology portfolio is generating stronger profitability than expected. BeOne Medicines Q2 earnings report
• Positive Sentiment: 2026 outlook raised: Management now expects full-year revenue of $6.6 billion to $6.8 billion, above the approximately $6.5 billion analyst consensus. The improved outlook indicates continued commercial momentum and gives investors greater confidence in the company’s growth trajectory. BeOne Medicines raises 2026 outlook
• Positive Sentiment: Analysts raised targets: TD Cowen increased its price target to $454 and assigned a Buy rating. Guggenheim raised its target to $430, Truist to $418 and Citizens JMP to $405, all with favorable ratings. These revisions suggest analysts see additional upside following the earnings report. Analyst price-target updates
• Neutral Sentiment: RBC remains bullish despite a small target reduction: Royal Bank of Canada lowered its target marginally to $450 but maintained an Outperform rating, signaling that the change does not materially weaken its investment view. RBC analyst update
• Neutral Sentiment: CFO stock sale: CFO Aaron Rosenberg sold 1,157 shares worth approximately $362,000 to cover tax withholding tied to vested equity awards. Because the transaction was tax-related rather than a discretionary sale, it is unlikely to materially affect sentiment. BeOne Medicines SEC insider filing

Insider Activity

In related news, SVP Chan Henry Lee sold 1,044 shares of the firm's stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $323.69, for a total transaction of $337,932.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Aaron Rosenberg sold 1,157 shares of BeOne Medicines stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $312.71, for a total transaction of $361,805.47. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 345,561 shares of company stock worth $105,625,947. Company insiders own 6.19% of the company's stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source